Literature DB >> 35069025

Fecal Diversion in Complex Perianal Fistulizing Crohn's Disease.

Takayuki Yamamoto1, Takahiro Shimoyama1.   

Abstract

Complex perianal Crohn's disease (CD) remains a challenging problem. Fecal stream is thought to be a trigger of disease progression in patients with CD. In patients with refractory perianal CD, diversion of fecal stream is sometimes required to alleviate clinical symptoms when medical and local surgical management are unsuccessful. Several studies evaluated the outcomes of fecal diversion for complex perianal CD. After fecal diversion, the majority of patients achieved early clinical response, but the prospect of restoring bowel continuity was low (approximately 20%). Nearly half of the patients eventually required proctectomy. A number of studies attempted to identify predictive factors for the outcomes of fecal diversion. Only rectal involvement was associated with unsuccessful restoration of bowel continuity. Biologic therapy did not seem to improve the efficacy of fecal diversion, although the evidence level was low because of insufficient data or methodological limitations. Based on these results, fecal diversion may be useful in alleviating clinical symptoms related to severe perianal CD and avoiding immediate proctectomy. The impact of biologic therapy on the outcomes of fecal diversion should be further investigated. Thieme. All rights reserved.

Entities:  

Keywords:  Crohn's disease; biologic therapy; fecal diversion; perianal Crohn's disease; proctectomy

Year:  2022        PMID: 35069025      PMCID: PMC8763458          DOI: 10.1055/s-0041-1740028

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  18 in total

1.  Guidelines for the multidisciplinary management of Crohn's perianal fistulas: summary statement.

Authors:  David A Schwartz; Leyla J Ghazi; Miguel Regueiro; Alessandro Fichera; Marco Zoccali; Eugene M W Ong; Koenraad J Mortelé
Journal:  Inflamm Bowel Dis       Date:  2015-04       Impact factor: 5.325

2.  Case series: does a combination of anti-tnf antibodies and transient ileal fecal stream diversion in severe Crohn's colitis with perianal fistula prevent definitive stoma?

Authors:  Mathieu Uzzan; Carmen Stefanescu; Léon Maggiori; Yves Panis; Yoram Bouhnik; Xavier Treton
Journal:  Am J Gastroenterol       Date:  2013-10       Impact factor: 10.864

3.  Loop ileostomy for anorectal Crohn's disease.

Authors:  D R Grant; Z Cohen; R S McLeod
Journal:  Can J Surg       Date:  1986-01       Impact factor: 2.089

4.  Diverting ileostomy or colostomy in the management of Crohn's disease of the colon.

Authors:  D C McIlrath
Journal:  Arch Surg       Date:  1971-08

5.  Natural history of perianal Crohn's disease after fecal diversion.

Authors:  Jenny Sauk; Deanna Nguyen; Vijay Yajnik; Hamed Khalili; Gauree Konijeti; Richard Hodin; Liliana Bordeianou; Paul Shellito; Patricia Sylla; Joshua Korzenik; Sonia Friedman; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 6.  Role of Fecal Diversion in Complex Crohn's Disease.

Authors:  John P Burke
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

7.  The effect of intra-abdominal resection or fecal diversion on perianal disease in pediatric Crohn's disease.

Authors:  B A Orkin; R L Telander
Journal:  J Pediatr Surg       Date:  1985-08       Impact factor: 2.545

Review 8.  Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease.

Authors:  S Singh; N S Ding; K L Mathis; P S Dulai; A M Farrell; J H Pemberton; A L Hart; W J Sandborn; E V Loftus
Journal:  Aliment Pharmacol Ther       Date:  2015-08-11       Impact factor: 8.171

9.  Long-term results of faecal diversion for refractory perianal Crohn's disease.

Authors:  J M Régimbeau; Y Panis; L Cazaban; M Pocard; Y Bouhnik; C Matuchansky; P Valleur
Journal:  Colorectal Dis       Date:  2001-07       Impact factor: 3.788

Review 10.  Fistula-associated anal carcinoma in Crohn's disease.

Authors:  Takayuki Yamamoto; Paulo Gustavo Kotze; Antonino Spinelli; Remo Panaccione
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2018-07-24       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.